103 related articles for article (PubMed ID: 28226191)
1. In reply to 'Hynes et al. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study'.
Park JH; Roxburgh CSD; Edwards J; Horgan PG; McMillan DC
Histopathology; 2017 Aug; 71(2):326-327. PubMed ID: 28226191
[No Abstract] [Full Text] [Related]
2. In reply to Hynes et al.: 'Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stages II/III colon cancer in a large population-based study'.
van Pelt GW; Huijbers A; Tollenaar RAEM; Mesker WE
Histopathology; 2018 Feb; 72(3):531-532. PubMed ID: 28898449
[No Abstract] [Full Text] [Related]
3. Response to Park et al. reply to 'Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study'.
Hynes SO; Coleman HG; Kelly PJ; Dunne PD; Salto-Tellez M; Loughrey MB
Histopathology; 2017 Aug; 71(2):327-329. PubMed ID: 28332733
[No Abstract] [Full Text] [Related]
4. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study.
Hynes SO; Coleman HG; Kelly PJ; Irwin S; O'Neill RF; Gray RT; McGready C; Dunne PD; McQuaid S; James JA; Salto-Tellez M; Loughrey MB
Histopathology; 2017 Jul; 71(1):12-26. PubMed ID: 28165633
[TBL] [Abstract][Full Text] [Related]
5. The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact.
van Pelt GW; Sandberg TP; Morreau H; Gelderblom H; van Krieken JHJM; Tollenaar RAEM; Mesker WE
Histopathology; 2018 Aug; 73(2):197-206. PubMed ID: 29457843
[TBL] [Abstract][Full Text] [Related]
6. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
[TBL] [Abstract][Full Text] [Related]
7. LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival.
Torres S; Garcia-Palmero I; Herrera M; Bartolomé RA; Peña C; Fernandez-Aceñero MJ; Padilla G; Peláez-García A; Lopez-Lucendo M; Rodriguez-Merlo R; García de Herreros A; Bonilla F; Casal JI
Clin Cancer Res; 2015 Nov; 21(21):4892-902. PubMed ID: 26206869
[TBL] [Abstract][Full Text] [Related]
8. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
9. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Sveen A; Nesbakken A; Ågesen TH; Guren MG; Tveit KM; Skotheim RI; Lothe RA
Clin Cancer Res; 2013 Dec; 19(24):6669-77. PubMed ID: 24166914
[TBL] [Abstract][Full Text] [Related]
10. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ
Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679
[TBL] [Abstract][Full Text] [Related]
11. Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients.
Brungs D; Aghmesheh M; de Souza P; Ng W; Chua W; Carolan M; Clingan P; Healey E; Rose J; Tubaro T; Ranson M
BMC Cancer; 2017 Apr; 17(1):251. PubMed ID: 28390415
[TBL] [Abstract][Full Text] [Related]
12. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.
Park JH; van Wyk H; Roxburgh CSD; Horgan PG; Edwards J; McMillan DC
Br J Cancer; 2017 May; 116(11):1444-1450. PubMed ID: 28427085
[TBL] [Abstract][Full Text] [Related]
13. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
[TBL] [Abstract][Full Text] [Related]
14. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
15. [TNM staging of cancer of the colon].
Hojo K
Gan No Rinsho; 1986 Aug; 32(10):1373-7. PubMed ID: 3783971
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of extramural deposits and extracapsular lymph node invasion in colon cancer.
Al Sahaf O; Myers E; Jawad M; Browne TJ; Winter DC; Redmond HP
Dis Colon Rectum; 2011 Aug; 54(8):982-8. PubMed ID: 21730787
[TBL] [Abstract][Full Text] [Related]
17. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Shen Y; Han X; Wang J; Wang S; Yang H; Lu SH; Shi Y
Sci Rep; 2016 Apr; 6():24310. PubMed ID: 27074743
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of occult nodal tumour cells in stage I and II colon cancer: The correlation between micrometastasis and disease recurrence.
Sloothaak DAM; van der Linden RLA; van de Velde CJH; Bemelman WA; Lips DJ; van der Linden JC; Doornewaard H; Tanis PJ; Bosscha K; van der Zaag ES; Buskens CJ
Eur J Surg Oncol; 2017 Aug; 43(8):1456-1462. PubMed ID: 28576463
[TBL] [Abstract][Full Text] [Related]
20. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
Poincloux L; Durando X; Seitz JF; Thivat E; Bardou VJ; Giovannini MH; Parriaux D; Barriere N; Giovannini M; Delpero JR; Monges G
Surg Oncol; 2009 Dec; 18(4):357-65. PubMed ID: 19027288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
